Combined cisplatin and radiation therapy for advanced bladder cancer.
Since September 1985, 44 patients with advanced urinary bladder cancer have been treated by combined cisplatin and full-dose radiotherapy. The patients were 32 males and 12 females, and their ages ranged from 33 to 83 years, with a median of 67.4 years. Radiotherapy consisting of a tumor dose of 50-60 Gy was administered with cobalt-60. Cisplatin was infused 5 days at a daily dose of 20 mg on the 1st and 4th weeks of treatment. Of the 39 evaluable patients 27 (69.2%) achieved a complete response. Toxicity was also evaluated for those 44 patients. Mainly gastrointestinal toxicity was noted: loss of appetite in 28 (64%), nausea and/or vomiting in 21 (48%), and diarrhea in 8 (18%). Leukocytopenia was noted in 16 (33%) and mild thrombocytopenia in 5 (11%). Mild dermatitis was noted in 8 (18%).
Matsushima
M
M
Department of Urology, Toho University School of Medicine, Tokyo, Japan.
Tajima
M
M
Kase
T
T
Harada
M
M
Takanami
M
M
Yagishita
T
T
Sawamura
Y
Y
Shirai
M
M
Kaneko
I
I
Kuwashima
A
A
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D011867:Radioisotope Teletherapy; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000628:therapy*
D003037:Cobalt Radioisotopes; D002945:Cisplatin